Neither has a controlled human trial for sports injuries. An FDA advisory panel voted 8 to 6 in July 2026 to back compounding BPC-157, but the FDA has not decided.
Recap by typeshit. Full story at the5krunner.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Cleveland Clinic notes there's little research and no official guidance on low-dose semaglutide, while trials show far smaller weight loss than standard dosing.
Johns Hopkins researchers report in Annals of Internal Medicine that the pill brought in new patients instead of pulling users away from injectable semaglutide.
Loading…